Hypereosinophilic syndrome (HES) is associated with a very high count of eosinophil in the blood. Eosinophils are a type of white blood cells and constitute a very important part of the immune system. An increased count of eosinophils usually indicates an infection or allergic reaction of the body. Hypereosinophilic syndrome is a rare blood condition and is characterized by persistent eosinophilia, higher counts of eosinophils than normal. In hypereosinophilic syndrome patients, the count of eosinophils is more than 1500/ml in the blood for six months or more. The cause for this condition is unknown. The continuous presence of high counts of eosinophils is associated with a wide range of clinical manifestations leading to organ tissue inflammation and eventually organ damage. The most commonly affected organs are skin, lungs, heart, and nervous system. HES can happen at any age, but is most common in adults. The symptoms of hypereosinophilic syndrome usually depend on the organ involved. Symptoms include skin rashes, memory loss, fatigue, fever, dizziness, anemia, vertigo, joint pain, and mouth sores. Diagnostic tests for the syndrome include bone marrow biopsy, blood tests, and echocardiography.
Increase in awareness regarding this condition, rise in investments by major players globally, increase in government initiatives, and rich product pipeline are expected to boost the hypereosinophilic syndrome market. Moreover, increased prevalence of various health conditions such as autoimmune disorders, endocrine disorders, and adrenal disorders, which result in hypereosinophilic syndrome is expected to propel the hypereosinophilic syndrome market. However, lack of knowledge about hypereosinophilic syndrome in developing regions, high cost of treatment, and poor health care infrastructure in developing countries are major factors estimated to restrain the hypereosinophilic syndrome market during the forecast period. Novel targeted therapies, including tyrosine kinase inhibitors and monoclonal antibodies, are some of the latest trends in the hypereosinophilic syndrome market.
The global hypereosinophilic syndrome market can be segmented based on drug, end-user, and region. In terms of drug, the hypereosinophilic syndrome market can be divided into benralizumab, dasatinibm, dexpramipexole, dihydrochloride, and others. The benralizumab segment held a prominent market share in 2017. It is expected to continue to dominate the hypereosinophilic syndrome market during the forecast period. This is mainly attributed to the wide use of benralizumab as the first line of treatment for eosinophilia. Based on end-user, the hypereosinophilic syndrome market can be categorized into hospitals, research centers, and clinic. The hospitals segment accounted for a significant market share in 2017. It is expected to maintain its leadership position from 2018 to 2026.
In terms of region, the global hypereosinophilic syndrome market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2017, due to high prevalence of autoimmune disorders, rise in the prevalence of cancer, and high awareness about various blood disorders. According to the America Autoimmune Related Disease Association (AARDA), approximately 50 million Americans suffered from autoimmune disorders in 2017, and their prevalence is still on the rise. According to American Cancers Society’s, Cancer statistic 2018, approximately 1,735,350 new cases of cancer will be diagnosed, and 609,640 cancer deaths are estimated in the U.S. in 2018. The hypereosinophilic syndrome market in Asia Pacific is expected to expand at a significant CAGR during the forecast period. The expected growth of the hypereosinophilic syndrome market in Asia Pacific can be attributed to a rise in awareness, increase in health care expenditure, and technological advancements in developing countries of the region.
Major players operating in the global hypereosinophilic syndrome market include GlaxoSmithKline plc. Bristol-Myers Squibb Company, Kyowa Hakko Kirin Co., Ltd., Knopp Biosciences LLC., Stemline Therapeutics, Inc., F. Hoffmann-La Roche Ltd, and Novartis AG.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.